20 Mar, 2015

Analyses of tramiprosate Phase 3 trials show improvement in cognition and function in APOE4 positive alzheimer’s disease subjects reaching 4 point improvement from placebo on ADAS-cog in homozygous APOE4 subjects, and support development of ALZ-801, a novel prodrug of tramiprosate with optimized drug properties

alzheon2019-09-23T12:10:54-04:00March 20th, 2015|

Read More

20 Mar, 2015

Lexington’s Alzheon gives its own Alzheimer’s news to rival Biogen’s

alzheon2019-09-23T12:10:54-04:00March 20th, 2015|Tags: bizjournals.com|

Read More

20 Mar, 2015

Alzheon Announces Phase 1 Results of ALZ-801, a First-in-Class Inhibitor of Amyloid Formation and Neurotoxicity for Alzheimer’s Disease

alzheon2019-09-23T12:10:54-04:00March 20th, 2015|

Read More

5 Jan, 2015

Alzheon Announces Patent Allowance in Europe for ALZ-801 in Development for Alzheimer’s Disease

alzheon2019-09-23T12:10:54-04:00January 5th, 2015|Tags: BioSpace.com|

Read More

5 Jan, 2015

Alzheon Appoints David Nikodem, Ph.D., to Board of Directors

alzheon2019-09-23T12:10:54-04:00January 5th, 2015|

Read More

5 Sep, 2014

Six drugs that could change the world

alzheon2019-09-23T12:10:54-04:00September 5th, 2014|Tags: bizjournals.com|

Read More

5 Sep, 2014

Alzheon Announces Patent Issuance in Japan for ALZ-801 in Development for Alzheimer’s Disease

alzheon2019-09-23T12:10:54-04:00September 5th, 2014|

Read More

15 Apr, 2014

Alzheon Appoints Franz Hefti, PhD, to Board of Directors

alzheon2020-06-26T16:54:35-04:00April 15th, 2014|

Read More

15 Apr, 2014

Alzheon Announces Notice of Allowance for U.S. Patent for its Lead Drug Candidate ALZ-801 in Clinical Development for Alzheimer’s Disease

alzheon2019-09-23T12:10:54-04:00April 15th, 2014|

Read More

19 Mar, 2014

Alzheon To Present At Two Upcoming Conferences: Geneva-Springfield Symposium on Advances in Alzheimer’s Therapy and BioCentury Future Leaders in the Biotech Industry

alzheon2020-06-26T16:54:22-04:00March 19th, 2014|

Read More